Company intelligence / Profile preview
Axonis Therapeutics
Boston/Cambridge, Massachusetts, United Statesaxonis.us ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Axonis Therapeutics has advanced its lead oral small molecule KCC2 potentiator, AXN‑027, into Phase 1 clinical trials targeting refractory epilepsy, chronic pain/neuropathic pain, and spinal cord injury. Preclinical data show restoration of excitation/inhibition balance in dysfunctional CNS circuits. The company’s pipeline includes additional small molecules and gene therapies aimed at neuroprotection and neural regeneration. Proof-of-concept studies have demonstrated efficacy in animal models of spinal cord injury, epilepsy, chronic pain, Rett syndrome, and more. No marketed drugs currently target KCC2 directly.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule drugsAAV-based gene therapyOral therapeutics
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Boston Children’s Hospital/Harvard Medical School/Université Laval (foundational research/licensing)SynGAP Research Fund collaborative grantGrant support from NIH, Department of Defense SCIRP program; CURE Epilepsy; Wings for Life; Massachusetts Life Center; Praxis Spinal Cord Institute; Creative Destruction Lab; Springboard Enterprises; MassChallenge
Beyond the preview
Go deeper on Axonis Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Axonis Therapeutics.